You are here

Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44AR049961-01
Agency Tracking Number: AR049961
Amount: $100,035.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
AGENNIX, INC. 8 GREENWAY PLZ, STE 910
HOUSTON, TX 77046
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOSE ENGELMAYER
 (713) 552-1091
 JENGELMAYER@AGENNIX.COM
Business Contact
Phone: (713) 552-1091
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant):
Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers.

There are 7.5 million US patients with chronic skin wounds with annual health care costs of $5-9 billion; diabetic ulcers alone cost $4 billion. Current therapies are inadequate with diabetic patients often developing gangrene and needing amputation.

Topical rhLF significantly enhanced wound healing in a mouse model, outperforming placebo as well as Regranex, the only biologic approved for chronic wounds. RhLF appears safe and well tolerated in humans, having been administered to 229 patients (topically and orally) without a drug-related serious adverse event. With a good safety profile and promising pre-clinical efficacy, rhLF may prove to be an effective and safe new drug for wound healing.

The aims of this study are to evaluate the clinical safety, pharmacokinetics and pharmacodynamics of topical rhLF in patients with diabetic ulcers. Up to 36 patients will be treated for fourteen days with escalating doses of rhLF. Safety will be evaluated clinically and by laboratory results. Incidence of partial and complete wound closure will also be observed. Safety results and any efficacy trends will be used to select rhLF doses for the proposed Phase II trial.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government